Related Experiment Videos
Topical corticosteroid therapy for acute radiation dermatitis: a prospective, randomized, double-blind study.
M Schmuth1, M A Wimmer, S Hofer
1Department of Dermatology, University of Innsbruck, Austria. matthias.schmuth@uibk.ac.at
The British Journal of Dermatology
|June 20, 2002
Summary
Topical corticosteroids and dexpanthenol can help manage radiation dermatitis symptoms during breast cancer therapy. Corticosteroids showed a slight advantage in reducing skin issues and improving quality of life.
Area of Science:
- Oncology
- Dermatology
- Radiotherapy
Background:
- Radiation dermatitis is a frequent complication of radiation therapy.
- There is no established consensus on the optimal treatment for radiation dermatitis.
Purpose of the Study:
- To compare the efficacy of topical 0.1% methylprednisolone versus 0.5% dexpanthenol for managing radiation dermatitis.
- To evaluate treatment effects on clinical symptoms, transepidermal water loss (TEWL), and quality of life (QOL) in breast cancer patients undergoing radiation therapy.
Main Methods:
- A randomized, double-blind study design was employed.
- Treatment initiation occurred at the start of radiation therapy and continued for two weeks post-treatment.
- Outcomes were assessed using clinical symptom scores, TEWL measurements, and QOL questionnaires.
Main Results:
- Both topical treatments delayed the onset of peak clinical symptoms and TEWL.
- Topical corticosteroids demonstrated a greater reduction in clinical symptoms and TEWL compared to dexpanthenol.
- While general QOL improved post-therapy, skin-related QOL declined, with corticosteroids showing a better reversal of this decline.
Conclusions:
- Prophylactic topical therapy with corticosteroids or dexpanthenol can ameliorate radiation dermatitis but not prevent it.
- Topical corticosteroids may offer a greater benefit than dexpanthenol for radiation dermatitis management.
- Further research with larger cohorts is necessary to establish optimal topical treatment strategies.